









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on June 2023

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil				
2) New Requests				
Hydrocortisone MR	RED			For HUTH paediatric endocrinology team only.
Cefiderocol	RED			ICB is the responsible commissioner.
Finerinine	AMB 2			The formulary will reflect the TAG – ICB is the responsible commissioner.
Eptinezumab	RED			The formulary will reflect the TAG – ICB is the responsible commissioner.
3) New formulations & extensions to use				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil				
4) Products considered by NICE				
TA880: Tezepelumab for treating severe asthma	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA879: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
None				

The following guidelines were presented to and approved at the June 2023 meeting of the APC:

- Amber Guidance for Orthostatic (Postural) Hypotension
- Amber 2 Guidance for Cenobamate
- IBD Guidance (HUTH only)

The following Green+ drug information leaflets were presented to and approved at the June 2023 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the June 2023 meeting of the APC:

- Nil

Other documents presented to and approved at the June 2023 meeting of the APC:

- Nil